OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

September 1st 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCC

September 1st 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

September 1st 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Dr. Garon on Antiangiogenic Agents in Lung Cancer

September 1st 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer

September 1st 2017

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.

Dr. Esteva on the Clinical Implications of Genomic Testing for Breast Cancer

September 1st 2017

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses the clinical implications of genomic testing in breast cancer.

Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer

August 31st 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Dr. Bunn on the MYSTIC Trial for Lung Cancer

August 31st 2017

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

Dr. Hu on the Next Steps for Biopsies in Prostate Cancer

August 30th 2017

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses the next steps of biopsies for patients with prostate cancer.

Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies

August 30th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

August 29th 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Dr. Campbell Discusses Advancements in Kidney Cancer Management

August 29th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.

Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

August 29th 2017

Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

August 29th 2017

Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Dr. Vokes on PARP Inhibitors for NSCLC

August 29th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

Dr. Nanus on Cytoreductive Nephrectomy for RCC

August 28th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses cytoreductive nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Siegel on Induction Therapy for Head and Neck Cancer

August 28th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses induction therapy for head and neck cancer.

Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

August 28th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.